cabozantinib,pembrolizumab,atezolizumab
merck,exelixis,roche
['atezolizumab', 'bladder', 'cabozantinib', 'pembrolizumab']
cabozantinib and atezolizumab showing response rates of 20-30% and os ~13 months in 1st line bladder cancer. this doesn t appear much greater than pembrolizumab alone from 361 or 52. in my opinion this probably shouldn t be explored further in 1st line disease. #asco22 
Interested in Urology Cancers, biomarkers and drug development.